FOLR1 and ovarian carcinoma: Clinical studies, including the SORAYA trial, have shown that MIRV provides significant antitumor activity with an acceptable safety profile in patients with recurrent ovarian cancer, leading to its accelerated FDA approval on November 14, 2022, for adults with FRα‐positive, platinum‐resistant ovarian cancer who had previously received one to three systemic treatments [18, 19].